Clinical Research Directory

Inclusion Criteria: * Recipients of first kidney transplants (deceased or living donor) with stable allograft function * 6 or more months after transplantation * Currently on a stable dose of twice-daily tacrolimus and mycophenolate mofetil (MMF) or enteric coated mycophenolic acid (EC-MPA)± corticosteroids for a minimum of 6 months prior (patient has remained on a dosing that has changed no greater than ± 0.5mg/dose for a minimum of 4 months) * Ability to comply with study procedures for the entire length of the study * Patient and/or parent/legal guardian has been informed about the study survey and has signed an informed consent form. Exclusion Criteria: * Detectable donor specific anti-HLA antibody prior to enrollment (pre- or post-transplant) * Actively being treated for an episode of biopsy proven acute cellular rejection (ACR) (Banff 1A or greater) * Post-transplant history of biopsy proven ACR (Banff 1B or greater) or antibody mediated rejection (AMR) * Currently receiving, planning to receive, or received within 7 days prior to study enrollment any drug interacting or interfering with tacrolimus metabolism (azole antifungals, erythromycin, clarithromycin, diltiazem, protease inhibitors, statins, grapefruit juice, rifampin or anti-seizure medications shown to interact with tacrolimus) * Currently receiving an mTOR inhibitor (sirolimus, everolimus) * Gastrointestinal illness that might affect the absorption of tacrolimus * Unable or unwilling to complete study survey questionnaire * Professional care taker is responsible for dispensing subject's medication * Recipient of HLA identical or zero HLA mismatched organ transplant * Documented history of medication non-adherence following transplantation prior to enrollment